Updates

News & Blog

Scientific breakthroughs, company milestones and the latest from our research labs.

28 July 20264 min read

Golgenia Closes €1.5 Million Series A to Advance its GSL Oncology Platform to First-in-Human Trials

Golgenia closes a €1.5M Series A led by Creadd Ventures, with Indaco Venture Partners SGR and Ruby Direct Opportunity Fund, to advance its glycosphingolipid-targeting oncology platform toward first pilot clinical trial.

Stay informed

Unlocking new horizons with Golgenia

Connect with us and discover how our research on Golgi glyco-oncogenes is shaping the future of cancer treatment.